Publications by authors named "Karla Bermudez Saint Andre"
Chronic GLP1 therapy reduces postprandial IL6 in obese humans with prediabetes.
Cardiovasc Endocrinol Metab
March 2024
Article Synopsis
- * In this small group of seven subjects, IL6 levels decreased after meals, while related markers like insulin and glucose showed significant changes during the therapy.
- * The findings suggest differences in GLP1-IL6 interactions between acute and chronic therapy, highlighting the need for further research to understand these mechanisms better.
Mechanisms underlying anti-diabetic effects of GLP1 analogs remain incompletely understood. We observed that in prediabetic humans exenatide treatment acutely induces interleukin-6 (IL-6) secretion by monocytes and IL-6 in systemic circulation. We hypothesized that GLP1 analogs signal through IL-6 in adipose tissue (AT) and used the mouse model to test if IL-6 receptor (IL-6R) signaling underlies the effects of the GLP1-IL-6 axis.
View Article and Find Full Text PDFArticle Synopsis
- * A randomized trial with 15 participants measured resting and peak blood flow responses, showing exenatide reduced resting blood flow compared to placebo, while saxagliptin had nonsignificant effects.
- * Exenatide also prevented a rise in triglycerides and post-meal glucose levels, indicating its unique role in managing vascular response and metabolic effects in this population.